ZIPSOR Drug Patent Profile

When do Zipsor patents expire, and when can generic versions of Zipsor launch?

Zipsor is a drug marketed by Assertio Speclty and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ZIPSOR is diclofenac potassium. There are forty-seven drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zipsor

A generic version of ZIPSOR was approved as diclofenac potassium by TEVA on August 6^th, 1998.

Summary for ZIPSOR

US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	5,166
Drug Prices:	Drug price information for ZIPSOR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZIPSOR
What excipients (inactive ingredients) are in ZIPSOR?	ZIPSOR excipients list
DailyMed Link:	ZIPSOR at DailyMed

See drug prices for ZIPSOR

See drug sales revenues for ZIPSOR

Recent Clinical Trials for ZIPSOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Depomed	Phase 4
Hospira, now a wholly owned subsidiary of Pfizer	Phase 1
Hospira, Inc.	Phase 1

See all ZIPSOR clinical trials

Pharmacology for ZIPSOR

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors
Physiological Effect	Decreased Prostaglandin Production

Paragraph IV (Patent) Challenges for ZIPSOR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZIPSOR	Capsules	diclofenac potassium	25 mg	022202	1	2012-11-14

US Patents and Regulatory Information for ZIPSOR

ZIPSOR is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Assertio Speclty	ZIPSOR	diclofenac potassium	CAPSULE;ORAL	022202-001	Jun 16, 2009	AB	RX	Yes	Yes	7,884,095
Assertio Speclty	ZIPSOR	diclofenac potassium	CAPSULE;ORAL	022202-001	Jun 16, 2009	AB	RX	Yes	Yes	7,939,518
Assertio Speclty	ZIPSOR	diclofenac potassium	CAPSULE;ORAL	022202-001	Jun 16, 2009	AB	RX	Yes	Yes	8,110,606
Assertio Speclty	ZIPSOR	diclofenac potassium	CAPSULE;ORAL	022202-001	Jun 16, 2009	AB	RX	Yes	Yes	7,662,858

Expired US Patents for ZIPSOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Assertio Speclty	ZIPSOR	diclofenac potassium	CAPSULE;ORAL	022202-001	Jun 16, 2009	6,287,594
Assertio Speclty	ZIPSOR	diclofenac potassium	CAPSULE;ORAL	022202-001	Jun 16, 2009	6,365,180

International Patents for ZIPSOR

See the table below for patents covering ZIPSOR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1049459	COMPOSITIONS LIQUIDES ORALES (ORAL LIQUID COMPOSITIONS)
Norway	20003698
Russian Federation	2252019	ПЕРОРАЛЬНЫЕ ЖИДКИЕ КОМПОЗИЦИИ (PERORAL LIQUID COMPOSITIONS)
Norway	20020208

ZIPSOR (diclofenac potassium) Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is ZIPSOR’s market foundation?

ZIPSOR is an oral formulation of diclofenac potassium indicated for acute pain (label-based use). It competes in the oral NSAID pain segment alongside branded and generic diclofenac products and other NSAIDs (both branded and generics). The market is characterized by:

• Rapid generics penetration typical of older small-molecule NSAIDs.
• Price compression driven by multi-source generic supply once exclusivity expires.
• Channel behavior that favors lower net cost and rebate intensity for common NSAID indications.
• Formulation substitution risk because efficacy is anchored to diclofenac exposure, and many competitors offer comparable clinical outcomes at lower prices.

In the US, ZIPSOR’s economics are shaped by its position after brand exclusivity and the resulting generic headwinds, with performance tied to net price, share preservation, and contracted channel uptake.

How has the competitive landscape evolved for diclofenac potassium?

The competitive structure for ZIPSOR is dominated by:

• Generic diclofenac potassium products after approval and market entry, which cap sustained premium pricing.
• Alternative NSAIDs (including other diclofenac salts and competing molecules) where physicians and health systems can substitute based on cost and formulary status.
• Formulary controls: payers frequently steer patients toward least-cost NSAIDs when clinical equivalence is acceptable.

This creates a market where ZIPSOR’s incremental value must show up as stability of demand at acceptable net pricing rather than sustained brand-level pricing power.

What drives demand for ZIPSOR in practice?

Demand is pulled by the acute pain use case and pushed by payer and prescriber behavior:

1. Prescriber switching within NSAIDs

   • Acute pain prescribing is highly substitutable across NSAIDs.
   • Once multiple low-cost options exist, continued brand use depends on habit, patient response history, and payer incentives.

2. Payer formulary placement

   • Preferred formulary tiers or incentives can sustain volume.
   • Loss of preferred status usually produces fast share erosion.

3. Net price and rebate intensity

   • NSAID net pricing is sensitive to rebate agreements and wholesaler buying patterns.
   • Financial trajectory is therefore driven more by contracted economics than by list price.

Where does ZIPSOR sit in the regulatory and exclusivity timeline?

ZIPSOR is a marketed prescription NSAID product; by definition, its market trajectory reflects the stage of life-cycle and exclusivity status common for diclofenac products in the US. The key dynamic is that once generic alternatives are widely available, brand revenue growth typically becomes structurally limited.

From a patent and lifecycle perspective, ZIPSOR’s sustained commercial performance depends on whether any later-expiring protections exist beyond the original exclusivity period. The practical outcome across this drug class has been persistent erosion of brand pricing power once generics enter.

What is the financial trajectory pattern typical for ZIPSOR’s drug class?

For older branded NSAIDs, the typical financial path is:

• Initial branded ramp driven by differentiation and exclusivity.
• Plateau as competing branded and generic products build.
• Downward inflection after generic availability, driven by:
  • Net price compression
  • Share loss to multi-source generics
  • Reduced payer acceptance of premium-priced brand

For ZIPSOR specifically, the market dynamic implies that the financial trajectory would track:

• Volume stability only if net pricing remains defensible and formularies keep brand access.
• Revenue decline if brand access weakens or generic pricing undercuts rapidly.

What matters most for ZIPSOR revenue: price or volume?

In a multi-source NSAID environment, revenue performance is usually more sensitive to price than to incremental volume:

• Price effect dominates because generic competition forces net price downward.
• Volume effect depends on formulary placement and whether prescribers keep using the brand at meaningful rates.
• Once the brand is no longer preferred, volume declines typically accelerate.

For business planning, the actionable read is that ZIPSOR’s financial trajectory should be treated as a function of:

• Net price under rebate and contract structure
• Formulary tier status by segment
• Brand share resistance (if any) through substitution inertia

How do current market mechanics affect near-term sales momentum?

Near-term sales momentum for a branded diclofenac potassium product tends to be governed by:

• Wholesale demand signals (buying patterns, re-stocking behavior)
• Payer updates (tiering changes, prior authorization rules)
• Competitive product positioning by formulary and PBM management
• Generic pricing volatility (affecting the gap between brand and generics)

These drivers create a compressed and unstable market environment where brand performance is usually not tied to clinical breakthrough but to contracting and access.

What are the investment-relevant indicators for ZIPSOR’s trajectory?

For stakeholders, the most decision-useful indicators are:

Indicator	What it signals	Why it matters for ZIPSOR
Net price trend	Effect of generic pressure and rebate intensity	Captures whether brand premium is sustainable
Generic penetration rate (diclofenac potassium)	Degree of multi-source share erosion	Predicts revenue slope acceleration
Formulary tier status shifts	Whether brand remains preferred	Drives volume retention vs rapid substitution
Channel inventory patterns	Whether demand is stable or being pulled forward	Impacts short-cycle sales volatility
Share vs other NSAIDs	Substitution to competing molecules	Determines whether losses stay within class or expand

What is ZIPSOR’s market outcome against its competitive set?

Given the highly substitutable nature of NSAID pain therapy and the broad availability of generic alternatives in the diclofenac and NSAID categories, ZIPSOR’s competitive outcome typically resolves as:

• Limited upside from differentiation after generic entry.
• Ongoing pressure from least-cost substitution by payers.
• Revenue sensitivity to access decisions and net price maintenance.

That market structure implies a financial trajectory more consistent with a mature branded asset facing erosion than a growth engine.

Data points available and what they imply

The available public information in the provided context supports a market-structure conclusion (NSAID substitution and generic pressure) but does not provide a verified, numeric financial time series (revenue, TRx, sales by year) for ZIPSOR itself. Under operational constraints, this response therefore focuses on validated market dynamics and lifecycle mechanics rather than presenting unsupported figures.

Key Takeaways

• ZIPSOR (diclofenac potassium) operates in a mature, highly substitutable NSAID market where generic competition caps pricing and formulary status drives volume.
• The drug’s financial trajectory is shaped primarily by net price compression and brand share loss after generic entry, typical for older small-molecule NSAIDs.
• Decision-useful monitoring should prioritize net price trend, formulary/PBM placement, and generic penetration, since these explain revenue slope more reliably than clinical factors.
• In this segment, “growth” is usually replaced by access management and contract economics.

---

FAQs

1) Is ZIPSOR insulated from generic substitution?

No. ZIPSOR competes in a class where generic equivalents drive substitution once available, making revenue sensitive to payer access and net pricing rather than differentiation.

2) What determines whether ZIPSOR maintains share?

Preferred formulary placement and contracting terms. When the brand is no longer preferred, substitution accelerates.

3) Is price or volume more important for ZIPSOR revenue?

In mature NSAID markets with multi-source competition, net price compression typically dominates revenue changes; volume follows formulary and access dynamics.

4) What is the most important near-term risk for ZIPSOR?

Losing payer preference or further net price deterioration as generic supply and PBM contracting intensify.

5) What would indicate a stabilizing financial trajectory?

Sustained net pricing through contracts plus stable formulary placement that preserves brand share relative to generic and alternative NSAIDs.

---

References

[1] US Food and Drug Administration. “Drug Approval Reports and Labeling for Diclofenac Potassium Products (ZIPSOR).” FDA, accessed 2026-04-25. https://www.fda.gov/